Review article · 2024 · Open access
Biofluid biomarkers for Alzheimer’s disease: past, present, and future
Medical Review, 4(6), 467–491 · Published 16 October 2024 · DOI 10.1515/mr-2023-0071
In brief
“Biofluid biomarkers for Alzheimer’s disease: past, present, and future” is a 2024 review article by Chengyu An and 5 co-authors, published in Medical Review. OpenAlex counts 14 citations as of 18 November 2026, which puts it in the top 2% of works published in 2024 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Medical Review.
- Citations
- 14
- Most cited in
- 2025 (8)
- Field-weighted impact
- 0.77
- References
- 239
- Authors
- 6
Abstract
Alzheimer's disease (AD) is a gradually progressive neurodegenerative disease with tremendous social and economic burden. Therefore, early and accurate diagnosis is imperative for effective treatment or prevention of the disease. Cerebrospinal fluid and blood biomarkers emerge as favorable diagnostic tools due to their relative accessibility and potential for widespread clinical use. This review focuses on the AT(N) biomarker system, which includes biomarkers reflecting AD core pathologies, amyloid deposition, and pathological tau, as well as neurodegeneration. Novel biomarkers associated with inflammation/immunity, synaptic dysfunction, vascular pathology, and α-synucleinopathy, which might contribute to either the pathogenesis or the clinical progression of AD, have also been discussed. Other emerging candidates including non-coding RNAs, metabolites, and extracellular vesicle-based markers have also enriched the biofluid biomarker landscape for AD. Moreover, the review discusses the current challenges of biofluid biomarkers in AD diagnosis and offers insights into the prospective future development.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024). Biofluid biomarkers for Alzheimer’s disease: past, present, and future. Medical Review, 4(6), 467–491. https://doi.org/10.1515/mr-2023-0071
MLA 9
An, Chengyu, et al. “Biofluid biomarkers for Alzheimer’s disease: past, present, and future.” Medical Review, vol. 4, no. 6, 2024, pp. 467–491. https://doi.org/10.1515/mr-2023-0071.
Chicago
An, Chengyu, Hui Cai, Ziye Ren, Xiaofeng Fu, Shuiyue Quan, and Longfei Jia. 2024. “Biofluid biomarkers for Alzheimer’s disease: past, present, and future.” Medical Review 4 (6): 467–491. https://doi.org/10.1515/mr-2023-0071.
Harvard
An, C. et al. (2024) ‘Biofluid biomarkers for Alzheimer’s disease: past, present, and future’, Medical Review, 4(6), pp. 467–491. doi:10.1515/mr-2023-0071.
IEEE
C. An, H. Cai, Z. Ren, X. Fu, S. Quan, and L. Jia, “Biofluid biomarkers for Alzheimer’s disease: past, present, and future,” Medical Review, vol. 4, no. 6, pp. 467–491, 2024, doi: 10.1515/mr-2023-0071.
BibTeX
@article{an2024biofluid,
title = {{Biofluid biomarkers for Alzheimer’s disease: past, present, and future}},
author = {An, Chengyu and Cai, Hui and Ren, Ziye and Fu, Xiaofeng and Quan, Shuiyue and Jia, Longfei},
journal = {Medical Review},
year = {2024},
volume = {4},
number = {6},
pages = {467--491},
doi = {10.1515/mr-2023-0071},
url = {https://doi.org/10.1515/mr-2023-0071}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Alzheimer's disease
- biofluid biomarkers
- cerebrospinal fluid biomarkers
- blood biomarkers
- amyloid deposition
- pathological tau
- neurodegeneration
- neuroinflammation
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
An, C., Cai, H., Ren, Z., Fu, X., Quan, S., & Jia, L. (2024). Biofluid biomarkers for Alzheimer’s disease: past, present, and future. Medical Review, 4(6), 467–491. https://doi.org/10.1515/mr-2023-0071
How many times has this paper been cited?
14 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Medical Review: sign in and open the full text from this page.
Who wrote this paper?
Chengyu An, Hui Cai, Ziye Ren, Xiaofeng Fu, Shuiyue Quan, Longfei Jia.
What is the DOI of this paper?
10.1515/mr-2023-0071, permanently at https://doi.org/10.1515/mr-2023-0071. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.